TORONTO (S&P Global Ratings) July 16, 2020--S&P Global Ratings today said that its ratings and outlook on U.S.-based Thermo Fisher Scientific Inc. (BBB+/Stable/A-2) are unchanged following the company's agreement to increase its bid for Netherlands-based life science and molecular diagnostic testing company Qiagen N.V. to €43 per share from €39, which will add just over $1.04 billion to the original acquisition price of roughly $11.5 billion. The increase in the acquisition price is within the $5 billion of additional capacity for tuck-in acquisitions that we estimated following the original Qiagen acquisition announcement. While Thermo Fisher's sales have been negatively affected by the COVID-19 related disruptions to research labs, it has also benefited from increased demand for its test kits and
